{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:43:39Z","timestamp":1749807819471},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T00:00:00Z","timestamp":1593302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.1093\/rheumatology\/keaa255","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T11:09:29Z","timestamp":1591873769000},"page":"e48-e49","source":"Crossref","is-referenced-by-count":2,"title":["Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply"],"prefix":"10.1093","volume":"59","author":[{"given":"Yoshikazu","family":"Nakaoka","sequence":"first","affiliation":[{"name":"Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Yamakido","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co. Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,28]]},"reference":[{"key":"2020082700373138300_keaa255-B1","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa253","article-title":"Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Watanabe","year":"2020","journal-title":"Rheumatology"},{"key":"2020082700373138300_keaa255-B2","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez630","article-title":"Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study","volume":"59","author":"Nakaoka","year":"2020","journal-title":"Rheumatology"},{"key":"2020082700373138300_keaa255-B3","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1253\/circj.CJ-11-1108","article-title":"Improved prognosis of Takayasu arteritis over the past decade\u2014comprehensive analysis of 106 patients","volume":"76","author":"Ohigashi","year":"2012","journal-title":"Circ J"},{"key":"2020082700373138300_keaa255-B4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2020082700373138300_keaa255-B5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijcard.2015.03.399","article-title":"Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis","volume":"187","author":"Arita","year":"2015","journal-title":"Int J Cardiol"},{"key":"2020082700373138300_keaa255-B6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-010-1694-9","article-title":"Takayasu arteritis: assessment of response to medical therapy based on clinical activity criteria and imaging techniques","volume":"32","author":"Freitas","year":"2012","journal-title":"Rheumatol Int"},{"key":"2020082700373138300_keaa255-B7","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/e48\/33686226\/keaa255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/9\/e48\/33686226\/keaa255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T04:38:01Z","timestamp":1598503081000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/9\/e48\/5864217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,28]]},"references-count":7,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,6,28]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa255","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,6,28]]}}}